![]() Grochowalski, Joseph H Liu, Ying Siedlecki, Karen L The results also indicated that demographic variables such as age and education do not play a significant role in the diagnosis of mild cognitive impaired patients based on the ADAS-Cog scores.Įxamining the reliability of ADAS-Cog change scores. The present study demonstrated that the ADAS-Cog is a promising tool for detecting and studying patients with mild cognitive impairment. We found that the total error score of the ADAS-Cog was the most reliable variable in detecting patients with mild cognitive impairment. Regardless of age and educational level, there were clear differences between the normal group and the Uncertain/MCI group, especially on the total error scores. Education was not significantly correlated with the ADAS-Cog scores in any group. Age was significantly correlated with total error score in the normal group, but there was no significant correlation between age and ADAS-Cog scores in the patient groups. The Uncertain/MCI group was significantly different from normal controls and Alzheimer disease CDR 0.5 or 1.0 groups on the ADAS-Cog except on a few non-memory subtests. The performances of the uncertain/mild cognitive impairment (MCI) patients on the Alzheimer Disease Assessment Scale- Cognitive ( ADAS-Cog) subscale were compared with those of normal controls, Alzheimer disease patients with CDR 0.5, and Alzheimer disease patients with CDR 1.0. Pyo, Geunyeong Elble, Rodger J Ala, Thomas Markwell, Stephen J The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale- cognitive subscale. This provides a boost to the efficiency of clinical trials requiring fewer patients and shorter durations for investigating disease-modifying treatments. The proposed scoring methodology significantly improves the sensitivity of the ADAS-Cog in measuring progression of cognitive impairment in clinical trials focused in the mild-to-moderate Alzheimer's disease stage. When validated on data from a real clinical trial, the ADAS-CogIRT methodology had higher sensitivity than the current scoring methodology in detecting the treatment effect. #Cogs 3 boyle trialThe ADAS-CogIRT methodology required significantly fewer patients and shorter trial durations as compared to the current scoring methodology when both were evaluated in simulated clinical trials. The ADAS-Cog was found to measure impairment in three cognitive domains of memory, language, and praxis. The sensitivity of the ADAS-CogIRT methodology was evaluated using clinical trial simulations as well as a negative clinical trial, which had shown an evidence of a treatment effect. Using item response theory, we developed a new scoring methodology ( ADAS-CogIRT) for the ADAS-Cog, which addresses several major limitations of the current scoring methodology. A major reason behind the low sensitivity is its sub-optimal scoring methodology, which can be improved to obtain better sensitivity. Verma, Nishant Beretvas, S Natasha Pascual, Belen Masdeu, Joseph C Markey, Mia KĪs currently used, the Alzheimer's Disease Assessment Scale- Cognitive subscale ( ADAS-Cog) has low sensitivity for measuring Alzheimer's disease progression in clinical trials. New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale- Cognitive subscale ( ADAS-Cog) in clinical trials. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |